{"id":15680,"date":"2025-12-04T12:55:14","date_gmt":"2025-12-04T07:25:14","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=15680"},"modified":"2025-12-04T12:56:31","modified_gmt":"2025-12-04T07:26:31","slug":"corona-remedies-ipo-opens-key-details-investors-shouldnt-miss","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/","title":{"rendered":"Corona Remedies IPO Opens: Key Details Investors Shouldn\u2019t Miss"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<p>In December 2025, India\u2019s IPO market continues to see strong traction, with several established companies heading to the primary market to capitalise on favourable investor sentiment. Pharma and <a href=\"https:\/\/www.torusdigital.com\/stocks\/sectors\/healthcare\">healthcare sector<\/a> remain among the most active sectors, supported by rising domestic demand and strong spending on specialty treatments across India. Against this backdrop, Corona Remedies Limited is set to open its <a href=\"https:\/\/torusdigital.com\/ipo\">IPO<\/a> on December 8, 2025, offering investors an opportunity to participate in one of the country\u2019s fast-growing pharmaceutical brands.<\/p>\n<p>Below is a detailed look at Corona Remedies Ltd., its IPO structure, financial performance, and competitive strengths.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"About_Corona_Remedies_Ltd\"><\/span><strong>About Corona Remedies Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company engaged in developing, manufacturing, and marketing products across key therapeutic areas, such as:<\/p>\n<ul>\n<li>Women\u2019s healthcare<\/li>\n<li>Cardiology<\/li>\n<li>Pain management<\/li>\n<li>Urology<\/li>\n<li>Multispecialty segments like vitamins\/minerals\/nutrition, gastrointestinal, and respiratory<\/li>\n<\/ul>\n<p>As of June 30, 2025, the company\u2019s portfolio includes 71 brands, with a strong presence in both specialist and mass-prescription categories.<\/p>\n<p>Corona Remedies has built a pan-India distribution network, with 2,671 medical representatives across 22 states, enabling deep reach among healthcare professionals, hospitals, and clinics.<\/p>\n<p>The company owns two manufacturing facilities in Gujarat, with a combined installed capacity of 1,285.44 million units per annum, supporting its large-scale production capability.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Corona_Remedies_Ltd_IPO_Details\"><\/span><strong>Corona Remedies Ltd. IPO Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <a href=\"https:\/\/www.torusdigital.com\/ipo\/corona-remedies-ltd-ipo\">Corona Remedies IPO<\/a> is a \u20b9655.37 crore book-built issue, consisting entirely of an Offer For Sale (OFS) of 61,71,101 shares. No fresh issue is included.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Key_IPO_Highlights\"><\/span><strong>Key IPO Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<tbody>\n<tr>\n<td>IPO Date<\/td>\n<td>December 8, 2025, to December 10, 2025<\/td>\n<\/tr>\n<tr>\n<td>Face Value<\/td>\n<td>\u20b910\u00a0per share<\/td>\n<\/tr>\n<tr>\n<td>Issue Price Band<\/td>\n<td>\u20b91008 to \u20b91062 per share<\/td>\n<\/tr>\n<tr>\n<td>Lot Size<\/td>\n<td>14 Shares<\/td>\n<\/tr>\n<tr>\n<td>Sale Type<\/td>\n<td>Offer For Sale<\/td>\n<\/tr>\n<tr>\n<td>Total Issue Size<\/td>\n<td>61,71,101\u00a0shares<br \/>\n(aggregating up to \u20b9655.37\u00a0Cr)<\/td>\n<\/tr>\n<tr>\n<td>Employee Discount<\/td>\n<td>\u20b954.00<\/td>\n<\/tr>\n<tr>\n<td>Issue Type<\/td>\n<td>Bookbuilding\u00a0IPO<\/td>\n<\/tr>\n<tr>\n<td>Listing At<\/td>\n<td>BSE, NSE<\/td>\n<\/tr>\n<tr>\n<td>Share Holding Pre Issue<\/td>\n<td>6,11,60,088\u00a0shares<\/td>\n<\/tr>\n<tr>\n<td>Share Holding Post Issue<\/td>\n<td>6,11,60,088\u00a0shares<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>promoters<\/strong> of the company are Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta, and Ankur Kirtikumar Mehta.<\/p>\n<p><a href=\"https:\/\/www.torusdigital.com\/stocks\/jm-financial-ltd-share-price\">JM Financial Ltd.<\/a> is the book-running lead manager, and Bigshare Services Pvt. Ltd. is the registrar of the issue.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Important_IPO_Timeline\"><\/span><strong>Important IPO Timeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Event<\/strong><\/td>\n<td><strong>Date<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>IPO Open Date<\/strong><\/td>\n<td>December 8, 2025<\/td>\n<\/tr>\n<tr>\n<td><strong>IPO Close Date<\/strong><\/td>\n<td>December 10, 2025<\/td>\n<\/tr>\n<tr>\n<td><strong>Allotment Date (Tentative)<\/strong><\/td>\n<td>December 11, 2025<\/td>\n<\/tr>\n<tr>\n<td><strong>Initiation of Refunds<\/strong><\/td>\n<td>December 12, 2025<\/td>\n<\/tr>\n<tr>\n<td><strong>Credit of Shares to Demat<\/strong><\/td>\n<td>December 12, 2025<\/td>\n<\/tr>\n<tr>\n<td><strong>Listing Date (Tentative)<\/strong><\/td>\n<td>December 15, 2025<\/td>\n<\/tr>\n<tr>\n<td><strong>UPI Mandate Deadline<\/strong><\/td>\n<td>5 PM on December 10, 2025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"IPO_Lot_Size\"><\/span><strong>IPO Lot Size<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Application Category<\/strong><\/td>\n<td><strong>Lots<\/strong><\/td>\n<td><strong>Shares<\/strong><\/td>\n<td><strong>Amount (\u20b9)<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Retail (Min)<\/strong><\/td>\n<td>1<\/td>\n<td>14<\/td>\n<td>14,868<\/td>\n<\/tr>\n<tr>\n<td><strong>Retail (Max)<\/strong><\/td>\n<td>13<\/td>\n<td>182<\/td>\n<td>1,93,284<\/td>\n<\/tr>\n<tr>\n<td><strong>S-HNI (Min)<\/strong><\/td>\n<td>14<\/td>\n<td>196<\/td>\n<td>2,08,152<\/td>\n<\/tr>\n<tr>\n<td><strong>S-HNI (Max)<\/strong><\/td>\n<td>67<\/td>\n<td>938<\/td>\n<td>9,96,156<\/td>\n<\/tr>\n<tr>\n<td><strong>B-HNI (Min)<\/strong><\/td>\n<td>68<\/td>\n<td>952<\/td>\n<td>10,11,024<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Corona_Remedies_Ltd_Financials\"><\/span><strong>Corona Remedies Ltd. Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Corona Remedies has demonstrated consistent growth across revenue and profitability over the years. Revenue increased 18%, while PAT surged 65% between FY24 and FY25.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Key_Financials_%E2%82%B9_Crore\"><\/span><strong>Key Financials (\u20b9 Crore)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Period Ended<\/strong><\/td>\n<td><strong>30 Jun 2025<\/strong><\/td>\n<td><strong>31 Mar 2025<\/strong><\/td>\n<td><strong>31 Mar 2024<\/strong><\/td>\n<td><strong>31 Mar 2023<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Assets<\/strong><\/td>\n<td>1,012.38<\/td>\n<td>929.86<\/td>\n<td>830.58<\/td>\n<td>595.02<\/td>\n<\/tr>\n<tr>\n<td><strong>Total Income<\/strong><\/td>\n<td>348.56<\/td>\n<td>1,202.35<\/td>\n<td>1,020.93<\/td>\n<td>891.10<\/td>\n<\/tr>\n<tr>\n<td><strong>Profit After Tax<\/strong><\/td>\n<td>46.20<\/td>\n<td>149.43<\/td>\n<td>90.50<\/td>\n<td>84.93<\/td>\n<\/tr>\n<tr>\n<td><strong>EBITDA<\/strong><\/td>\n<td>71.80<\/td>\n<td>245.91<\/td>\n<td>161.19<\/td>\n<td>135.03<\/td>\n<\/tr>\n<tr>\n<td><strong>Net Worth<\/strong><\/td>\n<td>607.02<\/td>\n<td>606.34<\/td>\n<td>480.41<\/td>\n<td>408.52<\/td>\n<\/tr>\n<tr>\n<td><strong>Reserves &amp; Surplus<\/strong><\/td>\n<td>545.86<\/td>\n<td>545.18<\/td>\n<td>419.25<\/td>\n<td>347.36<\/td>\n<\/tr>\n<tr>\n<td><strong>Total Borrowing<\/strong><\/td>\n<td>106.65<\/td>\n<td>62.70<\/td>\n<td>134.14<\/td>\n<td>2.33<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Key_Performance_Indicators_KPI\"><\/span><strong>Key Performance Indicators (KPI)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>KPI<\/strong><\/td>\n<td><strong>Value<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>ROE<\/strong><\/td>\n<td>27.50%<\/td>\n<\/tr>\n<tr>\n<td><strong>ROCE<\/strong><\/td>\n<td>41.32%<\/td>\n<\/tr>\n<tr>\n<td><strong>Debt\/Equity<\/strong><\/td>\n<td>0.10<\/td>\n<\/tr>\n<tr>\n<td><strong>RoNW<\/strong><\/td>\n<td>24.65%<\/td>\n<\/tr>\n<tr>\n<td><strong>PAT Margin<\/strong><\/td>\n<td>12.49%<\/td>\n<\/tr>\n<tr>\n<td><strong>EBITDA Margin<\/strong><\/td>\n<td>20.55%<\/td>\n<\/tr>\n<tr>\n<td><strong>Price to Book Value<\/strong><\/td>\n<td>10.71<\/td>\n<\/tr>\n<tr>\n<td><strong>Market Capitalisation<\/strong><\/td>\n<td>\u20b96,495.20 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Pre_Post_IPO_EPS_PE\"><\/span><strong>Pre &amp; Post IPO EPS &amp; P\/E<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Metric<\/strong><\/td>\n<td><strong>Pre IPO<\/strong><\/td>\n<td><strong>Post IPO<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>EPS (\u20b9)<\/strong><\/td>\n<td>24.43<\/td>\n<td>30.21<\/td>\n<\/tr>\n<tr>\n<td><strong>P\/E (x)<\/strong><\/td>\n<td>43.47<\/td>\n<td>35.15<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Corona_Remedies_Ltd_Industry_Outlook\"><\/span><strong>Corona Remedies Ltd.: Industry Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>The company ranks as the <strong>second fastest-growing pharmaceutical company<\/strong> in the top 30 Indian pharma players by domestic sales (MAT June 2022 to MAT June 2025).<\/li>\n<li>Strong demand across women\u2019s healthcare, cardiology, pain management, and multispecialty segments continues to drive growth in India\u2019s pharma market.<\/li>\n<li>With strong R&amp;D focus and Good Manufacturing Practices-compliant facilities, the company is well-prepared for long-term expansion.<\/li>\n<li>Growing healthcare spend and increasing access to speciality treatments create a favourable market backdrop for established pharma companies like Corona Remedies.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Corona_Remedies_IPO_Peer_Comparison\"><\/span><strong>Corona Remedies IPO: Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Corona Remedies IPO can be compared with peers such as <a href=\"https:\/\/www.torusdigital.com\/stocks\/abbott-india-ltd-share-price\">Abbott India Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/alkem-laboratories-ltd-share-price\">Alkem Laboratories Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/eris-lifesciences-ltd-share-price\">ERIS Lifesciences Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/glaxosmithkline-pharmaceuticals-ltd-share-price\">Glaxosmithkline Pharmaceuticals Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/j-b-chemicals-pharmaceuticals-ltd-share-price\">J B Chemicals &amp; Pharmaceuticals Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/mankind-pharma-ltd-share-price\">Mankind Pharma Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/pfizer-ltd-share-price\">Pfizer Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/sanofi-india-ltd-share-price\">Sanofi India Ltd<\/a>, and <a href=\"https:\/\/www.torusdigital.com\/stocks\/torrent-pharmaceuticals-ltd-share-price\">Torrent Pharmaceuticals Ltd<\/a>. Reviewing these companies helps investors understand Corona Remedies\u2019 positioning within the <a href=\"https:\/\/www.torusdigital.com\/stocks\/sectors\/pharmaceuticals\">Indian pharmaceutical sector<\/a>, offering useful insights into its scale, product mix, and competitive strength before making informed investment decisions.<\/p>\n<p><em><strong>People Also Read:<\/strong><\/em><\/p>\n<ul>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/methodhub-software-ipo-opens-key-details-investors-shouldnt-miss\/\">Methodhub Software IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/scalesauce-ipo-opens-key-details-investors-shouldnt-miss\/\">ScaleSauce IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/flywings-simulator-training-ipo-opens-key-details-investors-shouldnt-miss\/\">Flywings Simulator Training IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/luxury-time-ipo-opens-key-details-investors-shouldnt-miss\/\">Luxury Time IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/em><\/li>\n<li class=\"post-title\"><em><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/western-overseas-study-abroad-ipo-opens-key-details-investors-shouldnt-miss\/\">Western Overseas Study Abroad IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/em><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Corona Remedies Ltd. presents a compelling investment opportunity given its strong brand portfolio, growing presence across therapeutic categories, and robust pan-India distribution network. Its healthy financial growth, scalable manufacturing capabilities, and experienced leadership further enhance its market position.<\/p>\n<p>However, since the IPO is entirely an Offer For Sale (OFS), the proceeds will not directly contribute to business expansion. Investors should also evaluate competitive pressures and regulatory considerations within the pharmaceutical industry before making investment decisions.<\/p>\n<p>If you are exploring more investment opportunities, check out our dedicated page on\u202f<a href=\"https:\/\/www.torusdigital.com\/ipo\/upcoming-ipo\">upcoming IPO\u202flistings<\/a> to stay updated on the latest market offerings.<\/p>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;share_rating&#8221;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Rate this article<\/h6>\n<!-- FeedbackWP Plugin --><div  class=\"rmp-widgets-container rmp-wp-plugin rmp-main-container js-rmp-widgets-container js-rmp-widgets-container--15680 \"  data-post-id=\"15680\">    <!-- Rating widget -->  <div class=\"rmp-rating-widget js-rmp-rating-widget\">            <div class=\"rmp-rating-widget__icons\">      <ul class=\"rmp-rating-widget__icons-list js-rmp-rating-icons-list\">                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Terrible!\" data-value=\"1\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Bad!\" data-value=\"2\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Okay!\" data-value=\"3\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Good!\" data-value=\"4\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star rmp-icon--full-highlight\"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Great!\" data-value=\"5\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>              <\/ul>    <\/div>    <p class=\"rmp-rating-widget__hover-text js-rmp-hover-text\"><\/p>    <button class=\"rmp-rating-widget__submit-btn rmp-btn js-submit-rating-btn\">      Submit Rating    <\/button>    <p class=\"rmp-rating-widget__results js-rmp-results \">       <span class=\"rmp-rating-widget__results__rating js-rmp-avg-rating\">3.9<\/span> \/ 5.  <span class=\"rmp-rating-widget__results__votes js-rmp-vote-count\">7<\/span>    <\/p>    <p class=\"rmp-rating-widget__not-rated js-rmp-not-rated rmp-rating-widget__not-rated--hidden\">          <\/p>    <p class=\"rmp-rating-widget__msg js-rmp-msg\"><\/p>  <\/div>  <!--Structured data -->        <\/div>\n<div id=\"emoji-overlay\" style=\"display: none;\">\n<div id=\"overlay-emoji\"><\/div>\n<div id=\"overlay-description\" class=\"emoji-text\"><\/div>\n<\/div>\n<div id=\"rating-popup\">\n<p><span id=\"popup-close\">\u00d7<\/span><\/p>\n<div class=\"popup_message\">\n<div id=\"popup-emoji\"><\/div>\n<div class=\"popup_innermsg\">\n<h5>Thank You for Rating Our Article!<\/h5>\n<p>Your feedback is incredibly valuable to us, and we&#8217;re thrilled to hear your thoughts.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Share this article<\/h6>\n<div class=\"cscra-social square cscra-socials-679c8a1122c00\">\n        <a href=\"\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fcorona-remedies-ipo-opens-key-details-investors-shouldnt-miss%2F&t=Corona+Remedies+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"facebook\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Facebook\" target=\"_blank\"><i class=\"fa fa-facebook\"><\/i><\/a>\n        <a href=\"\/\/twitter.com\/intent\/tweet?text=Corona+Remedies+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fcorona-remedies-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"twitter\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Twitter\" target=\"_blank\"><i class=\"fa-brands fa-x-twitter\"><\/i><\/a>\n        <a href=\"https:\/\/api.whatsapp.com\/send?text=Corona+Remedies+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss - https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fcorona-remedies-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"whatsapp\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On WhatsApp\" target=\"_blank\"><i class=\"fa fa-whatsapp\"><\/i><\/a>\n        <a href=\"\/\/www.linkedin.com\/shareArticle?mini=true&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Fcorona-remedies-ipo-opens-key-details-investors-shouldnt-miss%2F&title=Corona+Remedies+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"linkedin\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Linkedin\" target=\"_blank\"><i class=\"fa fa-linkedin\"><\/i><\/a>\n    <\/div>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;] In December 2025, India\u2019s IPO market continues to see strong traction, with several established companies heading to the primary market to capitalise on favourable investor sentiment. Pharma and healthcare sector remain among the most active sectors, supported by rising domestic demand and strong spending on specialty treatments across India. Against","protected":false},"author":1,"featured_media":14110,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[5,169],"tags":[],"class_list":["post-15680","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Corona Remedies Ltd. IPO Opens: What Investors Need To Know<\/title>\n<meta name=\"description\" content=\"Corona Remedies Ltd. IPO is a \u20b9655.37 crore offer for sale in the pharmaceutical sector. Know the key details, financials, strengths, and important dates before investing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corona Remedies Ltd. IPO Opens: What Investors Need To Know\" \/>\n<meta property=\"og:description\" content=\"Corona Remedies Ltd. IPO is a \u20b9655.37 crore offer for sale in the pharmaceutical sector. Know the key details, financials, strengths, and important dates before investing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-04T07:25:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-04T07:26:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1441\" \/>\n\t<meta property=\"og:image:height\" content=\"466\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"torus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"torus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corona Remedies Ltd. IPO Opens: What Investors Need To Know","description":"Corona Remedies Ltd. IPO is a \u20b9655.37 crore offer for sale in the pharmaceutical sector. Know the key details, financials, strengths, and important dates before investing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/","og_locale":"en_US","og_type":"article","og_title":"Corona Remedies Ltd. IPO Opens: What Investors Need To Know","og_description":"Corona Remedies Ltd. IPO is a \u20b9655.37 crore offer for sale in the pharmaceutical sector. Know the key details, financials, strengths, and important dates before investing.","og_url":"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/","og_site_name":"Blog","article_published_time":"2025-12-04T07:25:14+00:00","article_modified_time":"2025-12-04T07:26:31+00:00","og_image":[{"width":1441,"height":466,"url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","type":"image\/webp"}],"author":"torus","twitter_card":"summary_large_image","twitter_misc":{"Written by":"torus","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/","url":"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/","name":"Corona Remedies Ltd. IPO Opens: What Investors Need To Know","isPartOf":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"image":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"thumbnailUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","datePublished":"2025-12-04T07:25:14+00:00","dateModified":"2025-12-04T07:26:31+00:00","author":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5"},"description":"Corona Remedies Ltd. IPO is a \u20b9655.37 crore offer for sale in the pharmaceutical sector. Know the key details, financials, strengths, and important dates before investing.","breadcrumb":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage","url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","contentUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","width":1441,"height":466},{"@type":"BreadcrumbList","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/corona-remedies-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Toruscope","item":"https:\/\/www.torusdigital.com\/toruscope\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.torusdigital.com\/toruscope\/.\/news\/"},{"@type":"ListItem","position":3,"name":"Corona Remedies IPO Opens: Key Details Investors Shouldn\u2019t Miss"}]},{"@type":"WebSite","@id":"https:\/\/www.torusdigital.com\/toruscope\/#website","url":"https:\/\/www.torusdigital.com\/toruscope\/","name":"Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.torusdigital.com\/toruscope\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5","name":"torus","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"torus"},"sameAs":["https:\/\/stage.torusdigital.com\/blogs"],"url":"https:\/\/www.torusdigital.com\/toruscope\/author\/torus\/"}]}},"_links":{"self":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/comments?post=15680"}],"version-history":[{"count":2,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15680\/revisions"}],"predecessor-version":[{"id":15682,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/15680\/revisions\/15682"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media\/14110"}],"wp:attachment":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media?parent=15680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/categories?post=15680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/tags?post=15680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}